Grifols (GRFS) Net Income towards Common Stockholders (2010 - 2020)
Grifols' (GRFS) quarterly Net Income towards Common Stockholders came in at $330.1 million in Q1 2020, up 69.41% YoY from $194.8 million in Q2 2019, and down 55.46% on a QoQ basis from $741.2 million in Q4 2019.
Grifols (GRFS) Net Income towards Common Stockholders (2010 - 2020) Analysis & Trends
Grifols (GRFS) has 11 years of Net Income towards Common Stockholders data on file, last reported at $330.1 million in Q1 2020.
- Quarterly Net Income towards Common Stockholders rose 69.41% year-over-year to $330.1 million in Q1 2020, while the trailing twelve-month figure through Dec 2021 was $330.1 million (down 69.19% YoY) and the FY2025 annual result came in at $467.9 million, up 178.92% from the prior year.
- Net Income towards Common Stockholders eased to $330.1 million in Q1 2020, from $741.2 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of $882.3 million in Q4 2017 to a low of $150.5 million in Q4 2016.
- A 5-year average of $374.7 million and a median of $260.5 million in 2018 frame the typical range for Net Income towards Common Stockholders.
- The widest YoY moves for Net Income towards Common Stockholders: up 486.37% in 2017, down 35.0% in 2017.
- Tracing GRFS's Net Income towards Common Stockholders over 5 years: stood at $150.5 million in 2016, then surged by 486.37% to $882.3 million in 2017, then declined by 9.06% to $802.4 million in 2018, then fell by 7.63% to $741.2 million in 2019, then slumped by 55.46% to $330.1 million in 2020.
- The last three Net Income towards Common Stockholders figures came in at $330.1 million (Q1 2020), $741.2 million (Q4 2019), and $194.8 million (Q1 2019), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 5.53 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 3.62 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | -1.34 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 3.26 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 2.51 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 2.38 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -10.50 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -238.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 583.63 Mn |
| 10 | Grifols | 5.45 Bn | 4.45 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 330.09 Mn |
| Dec 31, 2019 | 741.18 Mn |
| Mar 31, 2019 | 194.84 Mn |
| Dec 31, 2018 | 802.38 Mn |
| Jun 30, 2018 | 260.55 Mn |
| Mar 31, 2018 | 264.14 Mn |
| Dec 31, 2017 | 882.31 Mn |
| Jun 30, 2017 | 255.10 Mn |
| Mar 31, 2017 | 247.88 Mn |
| Dec 31, 2016 | 150.47 Mn |
| Sep 30, 2016 | 158.11 Mn |
| Jun 30, 2016 | 202.82 Mn |
| Mar 31, 2016 | 381.34 Mn |
| Dec 31, 2015 | 143.08 Mn |
| Sep 30, 2015 | 155.84 Mn |
| Jun 30, 2015 | 147.00 Mn |
| Mar 31, 2015 | 145.17 Mn |
| Dec 31, 2014 | 587.74 Mn |
| Sep 30, 2014 | 449.63 Mn |
| Jun 30, 2014 | 308.44 Mn |